TLS11a + CD3

TLS11a + CD3 is a *bispecific aptamer-antibody fusion molecule* designed for immunotherapy of hepatocellular carcinoma (HCC). It is composed of the **TLS11a aptamer** (a DNA or RNA sequence selected for high-affinity binding to HCC cells) and an **anti-CD3 antibody fragment** (single-chain variable region), chemically crosslinked to create a molecule that simultaneously binds HCC tumor cells and the CD3 receptor on T cells. This design specifically redirects cytotoxic T cells to lyse HCC tumor cells. Mechanistically, upon binding, TLS11a + CD3 induces T-cell activation, proliferation, cytotoxicity against tumor cells, and the release of multiple proinflammatory cytokines (IL-2, IL-6, IL-10, TNF-α, IFN-γ). The drug has demonstrated efficacy in preclinical *in vitro* and mouse xenograft models, showing tumor growth inhibition and prolonged survival. It represents an advanced form of bispecific T-cell engager (BiTE) technology using an aptamer for tumor targeting, rather than a traditional antibody-derived scFv. Preclinical development and characterization have been reported in academic research settings[1][2][3][5].

Other names

TLS11a/CD3TLS11a aptamer/CD3 antibody bispecific systemTLS11a-BiTETLS-11a-BiTETLS 11a-BiTE